Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell LymphomaBusiness Wire • 04/13/26
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology PlatformBusiness Wire • 04/07/26
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare DiseasesZacks Investment Research • 03/16/26
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal CancersBusiness Wire • 03/16/26
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026PRNewsWire • 03/12/26
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease DiagnosisBusiness Wire • 03/12/26
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/12/26
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference TranscriptSeeking Alpha • 03/05/26
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/04/26
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder PreservationBusiness Wire • 02/27/26
Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/27/26
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck CancerBusiness Wire • 02/24/26
Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/23/26
Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & DecisionsSeeking Alpha • 02/20/26